RxDoctor Payments Data

Miguel Culasso, MD

Family Medicine · Slidell, LANPI 1255334314

Payments from drug & device makers

$419in general payments, 2019–2025

Across 24 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$61
  • GSK$59
  • Boehringer Ingelheim$53
  • Edwards Lifesciences$53
  • Novo Nordisk$46
  • Exact Sciences$35
  • plus $112 from 7 others

What the payments were for

  • Food & beverage$419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$419 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,649
Medicare patients
142
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$128,543
JardianceEmpagliflozin89$89,659
RybelsusSemaglutide28$58,230
OzempicSemaglutide49$57,177
JanuviaSitagliptin Phosphate40$40,187
XareltoRivaroxaban26$30,247
Soliqua 100-33Insulin Glargine/Lixisenatide22$20,872
TrulicityDulaglutide12$19,241
LinzessLinaclotide17$16,763
MyrbetriqMirabegron11$11,814
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$10,667
Combivent RespimatIpratropium/Albuterol Sulfate12$8,978
SymbicortBudesonide/Formoterol Fumarate23$7,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,058
NexletolBempedoic Acid12$4,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$46$115,40877 claims
Boehringer IngelheimJardiance, Combivent Respimat$53$98,637101 claims
Johnson & JohnsonXarelto$13$30,24726 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$15$20,87222 claims
Lilly USA, LLCTrulicity$61$19,24112 claims
Astellas Pharma US IncMyrbetriq$18$11,81411 claims
GSKAnoro Ellipta$59$10,66720 claims
AstraZenecaSymbicort$13$7,04623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →